* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, August 3, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Go-to entertainment: why gaming was made for the toilet – The Guardian

    Why Gaming Is the Ultimate Way to Pass Time in the Bathroom

    Chicago Youth Symphony Orchestra takes the Lollapalooza stage – Yahoo Home

    Chicago Youth Symphony Orchestra takes the Lollapalooza stage – Yahoo Home

    Sens. Blackburn, Warnock introduce CREATE Act to provide tax relief to music creators – Yahoo Home

    Sens. Blackburn and Warnock Launch CREATE Act to Deliver Tax Relief for Music Creators

    That’s (Political) Entertainment: When Theatre Meets Politics

    Future Script: How Generative AI Is Changing Collective Bargaining in the Entertainment Industry – Jackson Lewis

    Future Script: How Generative AI Is Transforming Collective Bargaining in Entertainment

    The SBA’s live-entertainment bailout was supposed to end two years ago. We still don’t know how $1.5 billion was spent. – Yahoo Home

    $1.5 Billion Live-Entertainment Bailout: Two Years Later, Where Did the Money Go?

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Microsoft Seeks to Extend Access to OpenAI Technology – PYMNTS.com

    Microsoft Aims to Broaden Access to OpenAI Technology

    Livonia police use grappler technology to stop drunk driver – ClickOnDetroit | WDIV Local 4

    Livonia Police Deploy Grappler Technology to Safely Stop Drunk Driver

    Emory orthopaedic surgeons use robotic technology to transform knee replacement surgery – Emory News Center

    How Robotic Technology is Revolutionizing Knee Replacement Surgery

    Cognizant Technology Solutions Corp (CTSH) Q2 2025 Earnings Call Highlights: Strong Revenue … – Yahoo.co

    Cognizant Q2 2025 Earnings: Impressive Revenue Growth and Key Takeaways

    Revving Up The U.S. Technology Engine – Forbes

    Revving Up The U.S. Technology Engine – Forbes

    More than just a hockey player – Rochester Institute of Technology Athletics

    Beyond the Ice: The Inspiring Journey of a Remarkable Athlete from Rochester Institute of Technology

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Go-to entertainment: why gaming was made for the toilet – The Guardian

    Why Gaming Is the Ultimate Way to Pass Time in the Bathroom

    Chicago Youth Symphony Orchestra takes the Lollapalooza stage – Yahoo Home

    Chicago Youth Symphony Orchestra takes the Lollapalooza stage – Yahoo Home

    Sens. Blackburn, Warnock introduce CREATE Act to provide tax relief to music creators – Yahoo Home

    Sens. Blackburn and Warnock Launch CREATE Act to Deliver Tax Relief for Music Creators

    That’s (Political) Entertainment: When Theatre Meets Politics

    Future Script: How Generative AI Is Changing Collective Bargaining in the Entertainment Industry – Jackson Lewis

    Future Script: How Generative AI Is Transforming Collective Bargaining in Entertainment

    The SBA’s live-entertainment bailout was supposed to end two years ago. We still don’t know how $1.5 billion was spent. – Yahoo Home

    $1.5 Billion Live-Entertainment Bailout: Two Years Later, Where Did the Money Go?

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Microsoft Seeks to Extend Access to OpenAI Technology – PYMNTS.com

    Microsoft Aims to Broaden Access to OpenAI Technology

    Livonia police use grappler technology to stop drunk driver – ClickOnDetroit | WDIV Local 4

    Livonia Police Deploy Grappler Technology to Safely Stop Drunk Driver

    Emory orthopaedic surgeons use robotic technology to transform knee replacement surgery – Emory News Center

    How Robotic Technology is Revolutionizing Knee Replacement Surgery

    Cognizant Technology Solutions Corp (CTSH) Q2 2025 Earnings Call Highlights: Strong Revenue … – Yahoo.co

    Cognizant Q2 2025 Earnings: Impressive Revenue Growth and Key Takeaways

    Revving Up The U.S. Technology Engine – Forbes

    Revving Up The U.S. Technology Engine – Forbes

    More than just a hockey player – Rochester Institute of Technology Athletics

    Beyond the Ice: The Inspiring Journey of a Remarkable Athlete from Rochester Institute of Technology

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

January 29, 2024
in Health
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
Share on FacebookShare on Twitter

SAN FRANCISCO — The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings.

Patients treated with the immune checkpoint inhibitor (ICI) had a 38% reduced risk of death compared to patients on placebo, reported Tony Choueiri, MD, of the Dana-Farber Cancer Institute in Boston.

“Between 1973 and now, there have been 17 randomized controlled trials with over 12,000 patients with kidney cancer who were enrolled on adjuvant therapies on RCC, with zero survival improvement,” Choueiri said. “This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer,” he said at the Genitourinary Cancers Symposium (GuCS).

However, results from a second trial presented at GuCS offered less positive results: In part B of CheckMate 914, nivolumab (Opdivo) monotherapy as an adjuvant treatment failed to improve disease-free survival (DFS) versus placebo in patients with localized RCC at high risk of relapse after nephrectomy.

KEYNOTE-564

At a median follow up of 57.2 months, median OS was not reached in either trial arm, and resulted in an HR 0.62 (95% CI 0.44-0.87, P=0.002) in favor of pembrolizumab.

OS at 1 year was 98.6% with pembrolizumab versus 98.0% with placebo, while 4-year OS rates were 91.2% and 86.0%, respectively.

DFS results were similar to those demonstrated in an earlier interim analysis in which KEYNOTE-564 met its primary endpoint of DFS. In the latest analysis, adjuvant pembrolizumab reduced the risk of disease recurrence or death by 28% (HR 0.72, 95% CI, 0.59-0.87) compared to placebo.

The updated results “further support adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” Choueiri said.

The study enrolled 994 patients (median age 60; about 70% male) with high-risk clear cell RCC who were randomized to the two arms.

Most patients (over 90%) were categorized as M0, with about 85% M0 intermediate-high risk.

Treatment-related adverse events (TRAEs) occurred in 79.1% of patients in the pembrolizumab arm and 53.0% of patients in the placebo arm. Grade 3-4 TRAEs occurred in 18.6% and 1.2% of patients in the two arms, respectively.

TRAEs resulting in discontinuation of any treatment occurred in 18.2% and 0.8% of patients in the two arms.

No treatment-related deaths occurred.

CheckMate 914

Part A of the CheckMate-914 trial previously failed to show a DFS benefit with nivolumab plus ipilimumab (Yervoy) compared with placebo in patients with localized RCC at high risk of post-nephrectomy relapse.

Part B was designed to complement part A by also assessing adjuvant nivolumab monotherapy. It showed that at a median follow-up of 27 months and a median treatment duration of 5.1 months, median DFS was not reached in either the nivolumab or placebo arm (HR 0.87, 95% CI, 0.62-1.21, P=.396), reported Robert Motzer, MD, of Memorial Sloan Kettering Cancer Center in New York City.

At 18 months, DFS rates were 78.4% in the nivolumab arm and 75.4% in the placebo arm.

Thus, “the primary endpoint of DFS for nivolumab monotherapy was not met,” Motzer said.

Motzer added that because the primary endpoint of DFS was not reached, no formal OS analysis will be performed.

Part B included 825 patients — 411 assigned to the nivolumab arm, 208 to placebo, and 206 to nivolumab plus ipilimumab. These patients had a median age of 59, 93% had undergone radical nephrectomy, about 80% had pT3 tumors, while 7-8% had sarcomatoid features, and about 10% had PD-L1>1%.

Among select subgroups there was a trend favoring nivolumab in patients with sarcomatoid features, PD-L1 expression>1%, and those with a lower limit of normal hemoglobin at baseline.

Motzer also reported that DFS outcomes for nivolumab plus ipilimumab were similar in both parts A and B.

Why Only Pembrolizumab?

The results from CheckMate 914 are in line with similar immunotherapy trials that failed to show a DFS benefit as an adjuvant treatment in RCC, leading to the question of why pembrolizumab worked and other agents didn’t.

GuCS discussant Pedro C. Barata, MD, of the University Hospitals Seidman Cancer Center in Cleveland, said the answer to that question “is likely multifactorial.”

“I think factors like histology, different drugs, duration of treatment, patient characteristics like high risk, sarcomatoid features, safety profile, probably all played a role,” he said.

Barata noted that in looking at the DFS curve for KEYNOTE-564 “it’s important to remember that half of post-nephrectomy patients with high-risk features end up being cured and do not require adjuvant therapy.”

However, he added, when one weighs the risks and benefits of adjuvant therapy, “I think the scale tilts towards favoring adjuvant pembrolizumab; as we found out those patients live longer.”

Looking ahead, Barata said, more focus should be placed on how to better identify patients for adjuvant pembrolizumab; treat patients who progress on pembrolizumab; and clarify the role of that drug and other ICIs beyond clear cell RCC.

Disclosures

KEYNOTE 564 was funded by Merck Sharp & Dohme.

CheckMate 914 was funded by Bristol Myers Squibb (BMS). Some co-authors are company employees.

Choueiri and Motzer disclosed multiple relationships with industry.

Barata disclosed relationships with AstraZeneca, Aveo, Bayer, BMS, Caris Life Science, Eisai, EMD Serono, Exelixis, Merck, and Pfizer; institutional relationships with Dendreon, AstraZeneca, Bayer, Caris Life Sciences, Merck, Pfizer/Astellas; and institutional research funding from Aveo, Blue Earth Diagnostics, Exelixis, Merck, and Pfizer.

Primary Source

Genitourinary Cancers Symposium

Source Reference: Motzer R, et al “Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from part B of the randomized, phase 3 CheckMate 914 trial” GuCS 2024; Abstract LBA358.

Secondary Source

Genitourinary Cancers Symposium

Source Reference: Choueiri T, et al “Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma” GuCS 2024; Abstract LBA359.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/mgucs/108459

Tags: AdjuvantClearhealth
Previous Post

X hiring content moderators for a new ‘Trust and Safety’ center in Austin

Next Post

Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk

Study reveals China’s ecological red lines offer blueprint for biodiversity protection – Phys.org

Study reveals China’s ecological red lines offer blueprint for biodiversity protection – Phys.org

August 3, 2025
What do TSA bag scanners actually see? – Popular Science

What do TSA bag scanners actually see? – Popular Science

August 3, 2025
Why does your mind goes ‘blank’? New brain scans reveal the surprising answer – Live Science

Why does your mind goes ‘blank’? New brain scans reveal the surprising answer – Live Science

August 3, 2025
U.S. POINTER Study shows lifestyle program improves cognition in older adults – University of California – Davis Health

Lifestyle Program Boosts Cognitive Health in Older Adults, New Study Finds

August 3, 2025
World Championships, Day Eight Finals: Kliment Kolesnikov Blazes to Title in 50 Backstroke; Tie for Silver – Swimming World

Kliment Kolesnikov Blazes to Victory in 50 Backstroke as Day Eight of World Championships Ends with a Silver Medal Tie

August 3, 2025
Bond investors warm to risk, with Fed staying put in ‘Goldilocks’ economy – Reuters

Bond Investors Take Bold Steps as Fed Maintains Steady Course in a ‘Goldilocks’ Economy

August 3, 2025
Go-to entertainment: why gaming was made for the toilet – The Guardian

Why Gaming Is the Ultimate Way to Pass Time in the Bathroom

August 3, 2025
Covenant Health offers immunizations, activities for kids at Back to School Bash – KCBD

Covenant Health’s Back to School Bash: A Fun-Filled Immunization and Activities Event for Kids

August 3, 2025
Trump tells Schumer to ‘go to hell’ as Senate heads home after failed attempt to strike deal on nominees – CNN

Trump tells Schumer to ‘go to hell’ as Senate heads home after failed attempt to strike deal on nominees – CNN

August 3, 2025
Microsoft Seeks to Extend Access to OpenAI Technology – PYMNTS.com

Microsoft Aims to Broaden Access to OpenAI Technology

August 3, 2025

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (752)
  • Economy (777)
  • Entertainment (21,654)
  • General (16,263)
  • Health (9,814)
  • Lifestyle (785)
  • News (22,149)
  • People (777)
  • Politics (786)
  • Science (15,990)
  • Sports (21,272)
  • Technology (15,754)
  • World (758)

Recent News

Study reveals China’s ecological red lines offer blueprint for biodiversity protection – Phys.org

Study reveals China’s ecological red lines offer blueprint for biodiversity protection – Phys.org

August 3, 2025
What do TSA bag scanners actually see? – Popular Science

What do TSA bag scanners actually see? – Popular Science

August 3, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version